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Porcine corneas may be good substitutes for human corneas in donor shortage.
Therefore, we evaluated the efficacy and safety of an anti-CD40 antibody-based regimen compared with an anti-CD20 antibody-based regimen on the survival of full-thickness corneas in pig-to-rhesus xenotransplant. Thirteen Chinese rhesuses underwent full-thickness corneal xenotransplant. Six were administered anti-CD40 antibody, and the others were administered anti-CD20 antibody, basiliximab, and tacrolimus. Graft survival and changes in lymphocyte, donor-specific and antiGalα1,3Galβ1,4GlcNAc-R (αGal) antibody, and aqueous complement levels were evaluated. Treatment with the anti-CD40 antibody (>511, >422, >273, >203, >196, 41 days) and anti-CD20 antibody (>470, 297, >260, >210, >184, 134, >97 days) resulted in long-term survival of grafts. In the anti-CD20 group, the number of activated B cells was significantly lower than that in the anti-CD40 group, and the level of aqueous complements at 6 months was significantly higher than the preoperative level. There were no differences in the levels of T cells or donor-specific and antiαGal antibodies between the 2 groups. In the anti-CD20 group, 3 primates had adverse reactions. In conclusion, both the anti-CD40 antibody-and the anti-CD20
antibody-based protocols were effective for the long-term survival of full-thickness corneal xenografts, but the anti-CD40 antibody-based treatment had fewer adverse effects.
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| INTRODUC TI ON
Corneal transplant is the treatment of choice for corneal blindness.
1
Shortage of donor corneas and organ trafficking in developing countries are reasons to explore alternative treatments, including xenotransplant. [2] [3] [4] Current data on the clinical efficacies of pig-to-nonhuman primate (NHP) xenotransplant present encouraging outcomes in lamellar keratoplasty (LKP) or penetrating keratoplasty (PKP).
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The full-thickness corneal grafts of wild-type (WT) Seoul National University (SNU) miniature pigs show long-term survival in NHPs with anti-CD154 antibody (Ab)-mediated blockade. 6 Due to thromboembolism from the anti-CD154 Ab, we applied the anti-CD40
Ab instead and achieved long-term survival of LKP grafts in NHP models.
7
Given that PKP is widely used as the first-line procedure, 1 we aimed to develop a less toxic but effective immunosuppressant protocol for PKP. We hypothesized that an anti-CD40 Ab-based regimen or a commercially available regimen (anti-CD20 Ab/basiliximab/ tacrolimus) may be effective. We compared the efficacy and safety of an anti-CD40 Ab with those of an anti-CD20 Ab-based regimen in pig-to-rhesus full-thickness corneal transplant.
| MATERIAL S AND ME THODS
All procedures used in this study conformed to the ARVO Statement
Regarding the Use of Animals in Ophthalmic and Vision Research.
The primate study protocol was approved by the Research Ethics
Committee at SNU Hospital (IACUC No. 15-0171-S1A1). The following methods to evaluate efficacy and safety are basically the same as the methods used in our previous studies.
6,7
| Donors and recipients
Porcine corneas were obtained from pathogen-free SNU miniature WT pigs that had been inbred in the Xenotransplantation
Research Center at SNU (Table S1 ). Thirteen Chinese rhesus macaques were used as recipients (Table 1) . The NHPs were divided into 2 groups based on immunosuppressive regimen; 1 the anti-CD40 Ab-treated group (anti-CD40, n = 6) and 2 the combination regimen (anti-CD20 Ab/basiliximab/tacrolimus)-treated group (anti-CD20, n = 7).
| Orthotopic corneal transplant
All PKPs with sizes of 7.5/7.0 mm (donor/recipient) were performed by 1 surgeon, MK Kim, using the same technique described in a previous study. 
| Postoperative immunosuppressive regimen
All recipients received the same basic medications as follows 7 : 0.5% levofloxacin and 1% prednisolone acetate were topically administered once per day for 3 months. Dexamethasone at 1.5 mg/0.3 mL was subconjunctivally injected weekly for 6 months, and methylprednisolone was intramuscularly injected at an initial dosage of 2 mg/kg/day, which was tapered over 5 weeks. Intravenous immunoglobulin G (IVIG) was administered at a dosage of 1 g/kg on day 0 and after 2 weeks. Aflibercept (VEGF-trap, Eylea ® ; Regeneron, Tarrytown, NY; and Bayer HealthCare, Berlin, Germany) was subconjunctivally injected on day 0.
In the anti-CD40 group, a mouse-rhesus chimeric monoclo- 
| Clinical evaluations
Grading of rejection was performed by evaluating the opacity of the graft, the presence of edema, the vascularization of the graft, central corneal thickness (CCT), intraocular pressure (IOP), and density of endothelial cells (n = 10). 6, 7 The Kaplan-Meier survival curves were evaluated in both groups.
| Histology
Hematoxylin & eosin (H&E) and immunohistochemical/immunofluorescence stainings were performed as previously described. 6, 7 The primary Abs used are as follows: anti-CD68 Ab (1:100; Thermo 
| Memory T cell and B cell assays
Changes in memory T cell populations (CD28 + CD95 + central mem- were evaluated in whole blood and draining lymph nodes after the animals were killed. 6, 7 In the subjects with surviving grafts, cell changes were compared within the groups and between the groups before the operation and at 1 and 6 months.
| Donor pig-specific antibodies and anti-αGal/ anti-non-αGal antibody assays
Plasma concentrations of donor pig-specific IgM/IgG Abs were determined by the flow cross-match technique using donor peripheral blood mononuclear cells (PBMCs) as targeting cells. 7 Plasma levels of anti-αGal IgG and IgM Abs were measured by ELISA. 9 Their binding responses were assessed by flow cytometry using α1,
3-galactosyltransferase gene knockout (GTKO) porcine endothelial cell lines (PEC69) or WT porcine endothelial cells. The level of
Ab binding was determined as the net mean fluorescence intensity (MFI). In the subjects with surviving grafts, the changes were compared both within the groups and between the groups before the operation and at 1 and 6 months.
| Complement (C3a) assay
The concentration of C3a in the aqueous humor was evaluated by using commercial ELISA kits (BD OptEIA™ Human C3a ELISA Kit;
BD Biosciences, San Diego, CA) before the operation and at 1 and 6 months. 6, 7 In subjects with surviving grafts, the changes were compared both within the groups and between the groups.
| Statistical analyses
GraphPad Software (GraphPad Prism, Inc., La Jolla, CA) was used for statistical tests. Mean values of C3a concentration, T cells, Abs, and endothelial cell density were compared by using the Mann-Whitney U test for intergroup analysis or the Wilcoxon signed-rank test for intragroup analysis. Data are presented as the mean ± SE, except for the demographics data of donors and recipients. Statistical significance was indicated by P < .05.
| RE SULTS

| Clinical outcomes
The survival duration of grafts in the anti-CD40 group was >511, >422, >273, >203, >196, and 41 days, and that of grafts in the anti-CD20 group was >470, 297, >260, >210, >184, 134, and >97 days.
There was no significant difference in survival between the 2 groups (P = .6301, log-rank test, Table 1 The CCTs and IOPs of nonrejected NHPs were in normal ranges in both groups ( Figure 3A) . In rejected grafts, CCTs were dramatically increased immediately before the onset of rejection ( Figure 3B ). The densities of the endothelial cells were not decreased at 6 months after PKP in both groups (P > .05, Wilcoxon signed-rank test) ( Figure S1 ). The donor-recipient junctions were well adapted, and the corneal astigmatisms were within tolerable ranges ( Figure S2 ).
None of the primates had porcine endogenous retrovirus (PERV) and cytomegalovirus (CMV) infections ( Figure S3 ). Systemic adverse events that may be caused by immunosuppressants are shown in Table 2 . In the anti-CD40 group, no systemic side effects were observed. In the anti-CD20 group, 1 primate had loss of appetite, and another had pneumonitis, which was eventually controlled. A third primate (No. 6) had shigellosis but recovered within 1 week. At 2 months, the same primate (No. 6) showed abnormal blood profiles that suggested disseminated intravascular coagulation (DIC) without any clinical signs. The DIC-like blood profiles were normalized after discontinuation of tacrolimus and the administration of anticoagulants and steroid.
| Histology
H&E staining showed that surviving grafts in both groups had little inflammatory cell infiltration, and few lymphocytes were observed only in the donor-recipient junction ( Figure 4A,B) . However, extensive cellular infiltration and the retrocorneal membrane were observed in the rejected grafts in both groups ( Figure 4C ).
CD3
+ CD4 + T, CD3 + CD8 + T, and CD3 − CD20 + B lymphocytes and CD68 + macrophages were barely detected in the surviving grafts, while the rejected grafts were densely infiltrated by those inflammatory cells ( Figure 5 ).
| Anti-donor pig-specific Ab responses
Subjects with surviving grafts in both groups did not exhibit increase in the levels of anti-donor-specific IgM and IgG, except for the initial peak of IgG that was caused by nonspecific IgG of IVIG as previously described 7 ( Figure 6A ,B). There were no significant differences in the levels of IgM (P > .05, Mann-Whitney U test; Figure 6C ) and IgG (P > .05, Mann-Whitney U test; Figure 6D ) between subjects in the 2 groups with surviving grafts. There also was no statistically significant increase in IgM levels during follow-up in the subjects in the anti-CD40 group 
| Anti-Gal antibody responses and αGal expression in grafts
There were no significant differences in the levels of anti-αGal IgM and IgG and no significant changes in the MFI values of plasma samples against WT porcine endothelial cells (PECs) and GTKO PECs between subjects in the 2 groups with surviving grafts at 1 and 6 months (P > .05, Mann-Whitney U test, Figure 7A ,B), except as follows.
Preoperative MFI values against GTKO PECs were lower in the anti- No. 4) (×200, Figure 7E ).
| Changes in the concentrations of memory T and B cells in whole blood and draining lymph nodes of primates with surviving grafts
In the blood, there were no significant increases in the concentra- 
| C3a complement in aqueous humor
In the anti-CD40 group, there were no significant increases in the concentrations of C3a at 1 and 6 months compared with the preoperative levels among subjects with surviving grafts (P > .05, Friedman test; Figure 10 ). In contrast, in the anti-CD20 group, the level of aqueous C3a at 6 months was significantly higher than the preoperative level among subjects with surviving grafts (P = .0085, Friedman test).
| D ISCUSS I ON
Our study demonstrated that both anti-CD40 Ab-mediated blockade and the anti-CD20 Ab/basiliximab/tacrolimus regimen were effective for the long-term survival of full-thickness corneal xenotransplants in NHP studies. To our knowledge, this is the first report of a successful preclinical study of PKP with clinically available immunosuppressants. Anti-CD40 Ab-mediated blockade resulted in fewer systemic adverse reactions than the anti-CD20
Ab/basiliximab/tacrolimus regimen, although the difference was not significant. Although no cases of rejection occurred after LKP TA B L E 2 Immunosuppressive drug-related systemic side effects in anti-CD40 Ab and anti-CD20 Ab groups with the anti-CD40 Ab regimen, 7 PKP resulted in more cases of rejections (16.7%), suggesting that PKP is more xenogeneic. This is a reasonable result considering that the rejection rate of the allograft in PKP (which includes endothelial cells) is higher than that of the allograft in LKP (which does not include endothelial cells).
1
Consistent with previous studies, 10-12 our study also shows that corneal xenogeneic rejection is associated with both innate (complement and macrophages) and adaptive (type 1 helper T, CD4
and B cells, which produce Gal-specific IgG Abs as well as non-Gal IgG Abs) immunities. 6 Given that CD40 is constitutively expressed on B and dendritic cells, macrophages, monocytes, and eosinophils and transiently expressed on activated CD8 + T cells, 13 anti-CD40 anti-CD20 No. 3, POD 229) (×200) F I G U R E 6 Changes in plasma donor pig-specific IgM and IgG for 6 months. A, B. In the plasma of recipients in both groups who had surviving grafts, the levels of anti-donor-specific IgM and IgG did not increase, except for the initial peak of IgG that was caused by binding of nonspecific IgG of intravenously injected immunoglobulin. Two primates with rejected grafts showed increased levels of anti-donorspecific IgG, and the level of IgG was higher in anti-CD20 No. 2 than in anti-CD40 No. 4. C, D. There were no significant differences in the levels of IgM and IgG between subjects in the 2 groups with surviving grafts at preoperation and at postoperative 1 and 6 months (P > .05, Mann-Whitney test). Although the levels of IgG were significantly increased in the anti-CD40 group at 1 month compared with the preoperative level (P = .0239, Friedman test and Dunn multiple comparison test), the levels had decreased to the preoperative level at postoperative 6 months Ab-mediated blockade is effective in preventing rejection in PKP by suppressing adaptive cells as well as part of innate cells. This observation corresponds well with the other outcomes of organ transplant using an anti-CD40 Ab combined regimen. 14, 15 Taken together with our data, the use of anti-CD40 Ab can be considered as a promising option in clinical trials of corneal xenotransplant. The fact that 83.3%
of primates experience anterior synechia with anti-CD40 Ab-based protocols indicates that low-grade inflammation may still be present in the eyes although not at levels that would lead to graft rejection.
In high-risk PKPs, increased VEGF expression is known to induce corneal neovascularization, 16 and allograft rejection can be reduced with anti-VEGF treatment. 17 Considering that the anti-CD40 Ab- 
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Comparison of the concentration of T cells in draining lymph nodes between the anti-CD40 and anti-CD20 groups. A-C. There were no significant differences in the number of IFNγ-secreting CD4 + and CD8 + T cells or EM and CM T cells between the 2 groups at the time of sacrifice. (P > .05, Mann-Whitney U test). All data were analyzed after the subjects were killed (mean death time; anti-CD40 group POD 321 ± 139.8 and anti-CD20 group POD 253 ± 126.5) F I G U R E 1 0 Changes in the concentration of aqueous humor complement (C3a) in the anti-CD40 and anti-CD20 groups. There were no significant increases in the levels of C3a in aqueous humor at 1 and 6 months compared with the preoperative levels in recipients with surviving grafts in the anti-CD40 group (P > .05, Friedman test). In contrast, the concentration of aqueous C3a increased significantly at 6 months compared with the preoperative level in recipients with surviving grafts in the anti-CD20 group (**P = .0085, Friedman test)
